Compare Amgen, Inc. (AMGN) vs Diageo plc (DEO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Diageo plc — how do they compare? Amgen, Inc. trades at $356.4 (market cap $196.12B), while Diageo plc trades at $82.81 (market cap $44.73B). The key difference: Amgen, Inc. is far larger — about 4.4× Diageo plc's market cap, and Diageo plc pays the higher dividend (4.05%). Which is the better fit depends on your goals.
| AMGN | DEO | |
|---|---|---|
Market Cap | $196.12B | $44.73B |
Sector | Health | Technology |
52-Week High | $388.16 | $115.33 |
52-Week Low | $271.18 | $72.47 |
Enterprise Value | $241.41B | $65.55B |
Dividend Yield | 2.77% | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Diageo (DEO) trades at $82.03, up 1.76% with bearish technical signals but mixed fundamentals. The stock shows strong profitability with 12.19% net margins and 22.29% ROE, though recent earnings were mixed with a Q2 2025 miss. Analyst sentiment leans positive with 49% buy ratings, but technical indicators show 15 sell signals versus 1 buy. Recent news highlights CEO Dave Lewis's upcoming strategy update amid US market challenges and promotional increases to stabilize sales.
The outlook remains cautious due to weak US demand and competitive pressures, but valuation at multi-year lows and cost-saving initiatives offer potential upside. Key risks include execution on the new strategy and consumer spending trends. Investors should weigh the dividend yield and recovery potential against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →
